(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/159148 A3

(51) International Patent Classification:
A61K 31/407 (2006.01) *A61K 31/53* (2006.01)
A61K 31/4162 (2006.01) *C07D 487/04* (2006.01)

(21) International Application Number:
PCT/US2023/062771

(22) International Filing Date:
16 February 2023 (16.02.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/311,463 18 February 2022 (18.02.2022) US
PCT/US2022/075421 24 August 2022 (24.08.2022) US

(71) Applicant: **PTC THERAPEUTICS, INC.** [US/US]; 100 Corporate Court, South Plainfield, New Jersey 07080 (US).

(72) Inventors; and

(71) Applicants: **ZHANG, Xiaoyan**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **ALAM, Rauful**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **BEJCEK, Lauren**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **GILBERT, Bradley B.**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **HOSSEYNI, Seyedmorteza**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **HUARTE, Eduardo**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **LI, Jing**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **LIU, Yao**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **NIEDERER, Kyle**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **PARKER, Erica N.**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **PILLAI, Meenu**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **RASTELLI, Ettore**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **SYDORENKO, Nadiya**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **ZHANG, Nanjing**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **ZHENG, Tianyi**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **WOLL, Matthew G.**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US). **-, Handoko**; 100 Corporate Court, South Plainfield, New Jersey 07080 (US).

(74) Agent: **MARTIN, Paul T.** et al.; 100 Corporate Court, South Plainfield, New Jersey 07080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
05 October 2023 (05.10.2023)

WO 2023/159148 A3

(54) Title: INHIBITORS OF NLRP3

(57) Abstract: The present invention relates to compounds that are useful as inhibitors of NOD-like receptor protein 3 (NLRP3) inflammasome pathway, processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, methods of using said compounds in the treatment of various diseases and disorders, and medicaments containing them, and their use in diseases and disorders mediated by NLRP3.